# A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

Study · id `cardio:ct-nct01487109` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01487109](<https://clinicaltrials.gov/study/NCT01487109>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01487109

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.

## Technical summary

Registry record NCT01487109. Randomized; double masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2015-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 170 participants (enrolled count; ClinicalTrials.gov record NCT01487109, source copy `cardio:ctgov-nct01487109-2021-08-16`, retrieved 2026-10-26)
- Start date: 2012-01 (registry gives no type) (ClinicalTrials.gov record NCT01487109, source copy `cardio:ctgov-nct01487109-2021-08-16`, retrieved 2026-10-26)
- Primary completion: 2015-01 (actual) (ClinicalTrials.gov record NCT01487109, source copy `cardio:ctgov-nct01487109-2021-08-16`, retrieved 2026-10-26)
- Completion: 2015-01 (actual) (ClinicalTrials.gov record NCT01487109, source copy `cardio:ctgov-nct01487109-2021-08-16`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01487109, source copy `cardio:ctgov-nct01487109-2021-08-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01487109-2021-08-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
- Condition: Type 2 Diabetes Mellitus
- Condition: Chronic Kidney Disease
- Intervention (Drug): CTP-499
- Intervention (Drug): Placebo
- Lead sponsor: Concert Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: 49deeddfabfd640171b0c96cd80db66d82a41e3ef34c38845fdc831577af9e03
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
